The guidance is titled, “Best Practices in Developing Proprietary Names for Drugs” and can found

The industry will have a period of 60 days to submit comments to the docket. It is expected that a number of interested parties will submit comments in the coming weeks reflecting their recommendations for improvement to the new guidance.

If you have any questions on trademark related matters, please contact Terrence J. McAllister on (203) 327 4500 x135 or email at or Jeff Scepanski at